Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Recurrent Epithelial Ovarian Cancer Clinical Trial

Official title:

Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Sensitive Epithelial Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01334047
• Other study ID #: DC-006
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 2011
• Est. completion date: August 2013

Study information

• Verified date: February 2021
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study the investigators will include patients with relapsed epithelial ovarian cancer. In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Immunotherapy may have potential for consolidation therapy. Dendritic cell vaccine is well toleranted in previous studies, with minor side effects and no serious adverse events registrated In this study, patients will receive DC-vaccine therapy after response to platinum treatment at relapse. The investigtors include patients in good clinical condition with no severe symptoms of the disease. If patients relapse during vaccine treatment, they will be discontinued from the study.

The investigators have included hTERT- and survivin mRNA in addition to amplified cancer stem cell mRNA in the vaccine.

Description:

Study Period:

• Estimated date of first patient enrolled: First quarter of 2011

• Anticipated recruitment period: 3 years

• Estimated date of last patient completed: First quarter of 2017, follow up to 2022.

Treatment duration:

Patients will receive intradermal immunization once a week for 4 weeks followed by monthly "vaccine boost" during the first year. Patients that show immunological response will continue with vaccination every month the second and third year or as long as there is vaccine available. The patients will have follow up for 5 years or until progression of disease as evaluated by the investigator.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed epithelial ovarian cancer. Histologic documentation of the original primary tumor is required via pathology report.

• Completed first line treatment (surgery and adjuvant or neoadjuvant treatment with carboplatine and paclitaxel)

• Relapsed and platinum sensitive epithelial ovarian carcinoma patients with response to chemotherapy in recurrent disease

• If surgery is indicated, the patient should be surgically treated and then starts vaccination with a minimum interval of 28 days.

• Must be ambulatory with an ECOG performance status 0 or 1.

• Life expectancy = 6 months

• Must be of 18-75 years of age

• Must have lab values as the following:

• ANC = 1.5 x 109/L

• Platelets = 100 x 109/L

• Hb = 9 g/dL (= 5.6 mmol/L)

• Creatinine = 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance = 40 mL/min

• Bilirubin within the upper limit of normal

• ASAT and ALAT = 2.5 the upper limit of normal

• Albumin levels above lower normal value

• If the patient has preserved fertility after primary treatment, she must practice adequate contraception during the study treatment

• Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

• Eligible to otherwise curative treatment.

• History of prior malignancy, other than ovarian cancer, within the last 5 years, with the exception of curatively treated basal cell carcinoma and cancer in situ cervix uteri.

• Prior surgery within the past 28 days

• Clinical ascites or metastatic pleural fluid

• Active infection requiring antibiotic therapy.

• Have known active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis). Patients with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before study entry to rule out brain metastasis.

• Significant cardiac or other medical or mental illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, serious cardiac arrhythmia or psychosis.

• Pregnancy or lactation

• Previous adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.

• History of immunodeficiency or autoimmune disease such as but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis-dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.

• Positive for syphilis (treponema pallidum), HIV, Hepatitis B and C tests

• Use of systemic glucocorticoids.

• Prior anti-cancer treatment, including radiotherapy, chemotherapy immunotherapy and/or immunomodulating agents stopped for less than 4 weeks before first study treatment administration. Anti hormonal treatment, such as Tamoxifen, may continue until first study treatment administration.

• Any reason why, in the opinion of the investigator, the patient should not participate.

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Neoplasms
• Recurrent Epithelial Ovarian Cancer

Intervention

Biological:
• DC-006 vaccine
Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.

Locations

Country	Name	City	State
Norway	Oslo University Hospital- Norwegian Radium Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Steinar Aamdal

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency and severity of adverse events	Patients are coming every 4 weeks to the site during the 3 years vaccination period and every 6 months during the 5 years follow up period.; Biochemistry and hematology results, vital signs and ECOG performance status will be measured at those timepoints during vaccination period.	Up to 3 years
Secondary	Determine immunological response to the vaccine (induction of specific T-cell response)		8, 12 weeks after start of vaccination and every 3 months thereafter
Secondary	Determine time of disease progression and survival time.	Clinical response will be evaluated via: measurement of CA-125 every 4 weeks; physical examination every 3rd months during vaccination; CT taken every 3rd months during vaccinaton and every 3-6 months during follow up.	Every 4 weeks during vaccination and every 3-6 months during follow up
Secondary	Treatment free interval	Start date of new antineoplastic therapy since discontinuation of the study will be recorded to capture information regarding treatment free interval.	up to 5 years after vaccination